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Abstract
Once-daily two 600 mg tablets (1200 mg q.d.) raltegravir offers an easier treatment 
option compared to the twice-daily regimen of one 400 mg tablet. No pharmacoki-
netic, efficacy, or safety data of the 1200  mg q.d. regimen have been reported in 
pregnant women to date as it is challenging to collect these clinical data. This study 
aimed to develop a population pharmacokinetic (PopPK) model to predict the phar-
macokinetic profile of raltegravir 1200 mg q.d. in pregnant women and to discuss the 
expected pharmacodynamic properties of raltegravir 1200 mg q.d. during pregnancy 
based on previously reported concentration-effect relationships. Data from 11 phar-
macokinetic studies were pooled (n = 221). A two-compartment model with first-
order elimination and absorption through three sequential transit compartments best 
described the data. We assessed that the bio-availability of the 600 mg tablets was 
21% higher as the 400 mg tablets, and the bio-availability in pregnant women was 
49% lower. Monte–Carlo simulations were performed to predict the pharmacokinetic 
profile of 1200 mg q.d. in pregnant and nonpregnant women. The primary criteria 
for efficacy were that the lower bound of the 90% confidence interval (CI) of the 
concentration before next dose administration (Ctrough) geometric mean ratio (GMR) 
of simulated pregnant/nonpregnant women had to be greater than 0.75. The simulated 
raltegravir Ctrough GMR (90% CI) was 0.51 (0.41–0.63), hence not meeting the pri-
mary target for efficacy. Clinical data from two pregnant women using 1200 mg q.d. 
raltegravir showed a similar Ctrough ratio pregnant/nonpregnant. Our pharmacokinetic 
results support the current recommendation of not using the raltegravir 1200 mg q.d. 
regimen during pregnancy until more data on the exposure-response relationship be-
comes available.
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INTRODUCTION
Antiretroviral treatment is particularly important in pregnant 
women living with HIV, because adequate antiretroviral 
drug (ARV) therapy dramatically reduces the risk of mother-
to-child transmission of HIV.1,2 However, physiological 
changes during pregnancy often decrease the ARV exposure, 
as a result of hampered absorption, increased volume of dis-
tribution and/or increased metabolism and elimination.3,4 To 
ensure adequate ARV efficacy and safety, the pharmacoki-
netics of every ARV has to be examined in pregnant women 
living with HIV. Generally, it takes around 6 years to fill this 
knowledge gap after drug registration, during which pregnant 
women and their unborn babies are at risk for inadequate an-
tiviral therapy.5
In 2017, a novel raltegravir formulation was granted 
market authorization. This once-daily (q.d.) regimen of two 
600  mg tablets (1200  mg q.d.) offers an easier treatment 
option compared with the twice-daily (b.i.d.) regimen of 
one 400 mg tablet (400 mg b.i.d.). The raltegravir 1200 mg 
q.d. regimen demonstrated non-inferior efficacy and simi-
lar safety to the 400 mg b.i.d. regimen at 96 weeks.6,7 The 
600 mg formulation can be dosed once-daily because of the 
less erratic absorption, higher bioavailability, higher loading 
dose and decreased influence of concomitant food intake.8 
When dosed as 1200 mg q.d. the mean raltegravir Ctrough is 
38% lower compared with dosing as 400 mg b.i.d., making 
this regimen theoretically more sensitive for possible con-
centration lowering influences, such as drug-drug interaction 
and pregnancy.8 No clinical pharmacokinetic, efficacy, or 
safety data of the 600  mg formulation in pregnant women 
exists up to date, and therefore this formulation is not recom-
mended to be used during pregnancy.
The raltegravir 400 mg b.i.d. regimen is among the pre-
ferred regimens for pregnant women in high-income settings, 
as it produces rapid viral load decline, has low potential for 
drug-drug interactions and the experience with its use in 
pregnancy is growing.1,9 Pharmacokinetic data showed that 
the raltegravir exposure decreases on average by 29%–54% 
in pregnant women treated with raltegravir 400 mg b.i.d.10,11 
The sufficient rate of virologic response, large pharmacoki-
netic variability, and debatable concentration-efficacy rela-
tionship led to the conclusion that the decreased exposure of 
the b.i.d.-regimen during pregnancy would not be of clinical 
relevance.10,11
The concentration-efficacy relationship is debatable for 
raltegravir; no relationship could be observed for the 400 mg 
b.i.d. and 1200 mg q.d. regimen up to date.12 However, a re-
lationship has been observed for the raltegravir 800 mg q.d. 
regimen. This regimen demonstrated inferiority in achiev-
ing HIV RNA  <  50 copies/ml compared with the 400  mg 
b.i.d. regimen.13 Logistic regression models and a receiver 
operating characteristic (ROC) curve showed that individuals 
with a Ctrough < 0.020 mg/L had a greater chance of failing 
to achieve viral suppression, although the sensitivity was low 
(45%) and the specificity moderate (75%).12 The mean Ctrough 
of patients treated with raltegravir 800 mg q.d. (0.018 mg/L) 
was lower as the observed mean Ctrough of pregnant patients 
treated with 400 mg b.i.d. (0.064 and 0.077 mg/L), indicat-
ing efficacy of this regimen during pregnancy.10,11,13 This 
also suggests no concentration-effect relationship could be 
observed for the 400 mg b.i.d. because the pharmacokinetic 
parameters remain above the minimum concentration needed 
for efficacy.12
The availability of multiple proven effective and safe 
alternative ARVs makes it challenging, or even impossi-
ble, to timely collect clinical pharmacokinetic data of the 
raltegravir 1200 mg q.d. regimen in pregnant women. As 
the formulation, dosage, and dosing schedule differ for the 
1200 mg q.d., we cannot directly apply the findings from 
the pharmacokinetic studies in pregnant women treated 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON 
THE TOPIC?
The twice-daily regimen of one 400 mg raltegravir 
tablet is among the preferred regimens for pregnant 
women and adequate clinical, pharmacokinetic, and 
safety data is available. However, such data do not 
exist for the once-daily regimen of two 600 mg ralte-
gravir tablets.
WHAT QUESTION DID THIS STUDY 
ADDRESS?
Is the 1200  mg once-daily raltegravir regimen an 
effective treatment option during pregnancy based 
on the estimated pharmacokinetic profile and the ex-
pected pharmacodynamic properties of this regimen?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
Simulations with the developed population phar-
macokinetic (PopPK) model suggested inadequate 
raltegravir exposure in third trimester women using 
raltegravir 1200 mg q.d.
HOW MIGHT THIS CHANGE DRUG 
DISCOVERY, DEVELOPMENT, AND/OR 
THERAPEUTICS?
This PopPK model serves as an in silico prediction 
tool to predict raltegravir exposure in various popu-
lations using the 400 mg and 600 mg tablet formula-
tions. Predictions showed restraining the once-daily 
raltegravir regimen in pregnant women seems rea-
sonable until more data become available.
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with 400 mg b.i.d. raltegravir. A population pharmacoki-
netic (PopPK) model can be used to characterize the con-
centration-time course of a drug for individual subjects, 
and to simulate concentration-time profiles under varying 
conditions as different dosing regimens and populations. 
This approach enables a timely assessment of the appli-
cability a new formulation in pregnant women without 
putting a variety of women at risk. This study aims to (a) 
develop a PopPK model for raltegravir in individuals with 
and without HIV-infection (400 mg and 600 mg formula-
tions), including pregnant women (400  mg formulation), 
(b) to predict the pharmacokinetic profile of raltegravir 
1200  mg q.d. in pregnant women, and (c) to discuss the 
expected pharmacodynamic characteristic of raltegravir 




Data from 11 pharmacokinetic studies with raltegravir and 
rich sampling schedules were pooled.8,10,14–21 These stud-
ies include a combination of healthy and HIV-infected sub-
jects taking 400  mg and 600  mg raltegravir tablets, and 
pregnant subjects taking the 400  mg tablets. The study 
protocols and subject characteristics are summarized 
in Table  1, and detailed information can be found in the 
original publications.8,10,14–21 Twenty-two European, HIV-
infected, pregnant women treated with a 400  mg b.i.d. 
raltegravir-based regimen were included to determine the 
effect of pregnancy on the pharmacokinetics of raltegra-
vir.10 These women underwent intensive pharmacokinetic 
sampling during the third trimester (preferably at 33 weeks 
gestation) and postpartum (4–6 weeks after giving birth). 




A PopPK model was developed using NONMEM 7.4 
(ICON Development Solutions, Hanover, MD, USA). The 
first-order conditional estimation method with eta-epsilon 
interaction was used. Pirana 2.9.7 (Certara, Princeton, 
NJ, USA) was used as an interface to NONMEM and to 
structure and document model development, R 3.5.3 (R 
Foundation for Statistical Computing, Vienna, Austria) for 
data management, graphical visualization, and evaluation, 
and Perl speaks NONMEM (PsN) for automation of a di-
verse range of processes related to model development.22
Several PopPK models have previously been developed for 
healthy or HIV-infected children and adults treated with ralte-
gravir 400 mg tablets.23–26 However, visual predictive checks 
(VPCs) showed none of these models was able to directly 
describe the absorption and elimination profile adequately 
in our larger dataset. Model development was conducted in 
a step-wise fashion.27 We started with the pharmacokinetic 
data of healthy subjects using raltegravir 1200 mg q.d., be-
cause this regimen has a less variable absorption and a longer 
dosing interval, facilitating estimation of the primary phar-
macokinetic parameters. Subsequently, the data of healthy 
subjects using raltegravir 400 mg b.i.d., patients living with 
HIV using raltegravir 1200 mg q.d., patients living with HIV 
using raltegravir 400 mg b.i.d., and pregnant women living 
with HIV using raltegravir 400 mg b.i.d. were added step-
wise. The model structure was re-evaluated after each round, 
including new data.
One, two, and three compartment models were evaluated. 
First- and zero-order (dual) absorption models, entero-hepatic 
recirculation, mixture, and transit absorption models were 
evaluated to describe the variable absorption of raltegravir. 
Model selection was based on maximum likelihood statistics 
(quantified by the objective function value [OFV]), with a 5% 
significance level (dOFV 3.84), physiological plausibility, 
precision in parameters estimates, standard goodness-of-fits 
plots, and VPCs.
The typical bioavailability (F) value was set to 1, because 
no intravenous data were available to allow for estimation of 
the absolute bioavailability. For the stochastic component of 
the model, log-normal and box-cox transformed distributions 
for the interindividual variability (IIV) and interoccasion 
variability (IOV) between doses were tested.28,29 Normally 
distributed additive, proportional, and combined resid-
ual error model structures were tested, next to a dynamic 
transform-both-sides approach, which allows estimation of 
both the shape and scedasticity parameters.29 In addition, 
a time-varying approach to empirically account for model 
errors resulting from the erratic and highly variable absorp-
tion of raltegravir was tested with a different proportional 
error for the time before and after 3 h (the average timepoint 
for maximum concentration [Cmax]).
2,30 The lower limit of 
quantification (LLOQ) of the different studies are shown in 
Table  1. Below the limit of quantification (BLOQ) values 
were included as LLOQ divided by 2 (1% of the total sam-
ples). The consecutive BLOQ values in the elimination phase 
and the predose BLOQ samples of single-dose studies were 
excluded (2% of the total samples).
All flow and volume parameters were scaled with body 
weight according allometric theory, with fixed allometric ex-
ponents of 0.75 for flow parameters and 1 for volumes of 
distribution.31 For pregnant women, postpartum weight was 
used because applicability of allometric scaling for pregnant 
women has not been established and could confound the 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































   | 165ONCE-DAILY RALTEGRAVIR IN PREGNANT WOMEN
potential pregnancy effect.31 In the case of missing postpar-
tum weight (n = 4), the weight was calculated from the third 
trimester weight times the mean difference between third tri-
mester and postpartum weight (−7%).
Covariate testing was based on physiological plausibility 
and results from previous population pharmacokinetic models. 
Sex was tested as covariate on F, and White ethnicity as covari-
ate on central volume of distribution (Vc).24 We tested ataza-
navir and efavirenz co-administration as covariates on F and 
CL.19,20,32 Pregnancy was tested as a dichotomous covariate on 
CL, mean absorption time (MAT), F, Vc, and absorption rate 
(Ka).3 Covariate-parameter relations were evaluated using a 
forward inclusion and backward elimination approach. The se-
lection was based on biological plausibility, previous models, 
and maximum likelihood statistics (quantified by a 5% signifi-
cance level [dOFV 3.84]) applied for likelihood ratio testing of 
nested models. Because the pregnancy covariate was the most 
defining covariate, this covariate was evaluated extensively. A 
sensitivity analysis was performed for all significant covariate 
effects of pregnancy separately. This means that separate sim-
ulations were carried out and that we evaluated whether the 
choice for a covariate pregnancy defined the conclusion based 
on our primary end point.
Different meal types have considerable and variable effect 
on the pharmacokinetic profile of raltegravir.8,33 A low-fat 
meal compared with fasted conditions decreases raltegra-
vir exposure for the 400  mg and 600  mg tablets in a sim-
ilar matter.8 The pharmacokinetic profile of raltegravir is 
not meaningfully altered by a moderate-fat meal, whereas 
the exposure is increased with a high-fat meal and this ef-
fect is more pronounced for the 400 mg formulation than the 
600 mg formulation.8,33 Only data of the 600 mg formulation 
across different meal types was available to us. The effect of 
food (irrespective of meal type), a low-fat meal (389  kcal, 
6.9% fat) and a moderate-fat meal (650–844 kcal, 48% fat) 
as a covariate on F and MAT in subjects using the 600 mg 
formulation was tested, assuming a similar food effect for the 
400 mg formulation. The studies examining the 400 mg ralte-
gravir formulation were performed under fasted or moderate 
fat conditions, as shown in Table 1.
Simulations
To predict the pharmacokinetic profile of raltegravir 
1200  mg q.d. in pregnant and nonpregnant individuals, 
simulations with the final model were performed. Monte-
Carlo simulations with 3000 individuals with multilevels of 
random effect (parameter uncertainty, IOV, and IIV) were 
conducted. The procedure was repeated 1000 times using 
Stochastic Simulation and Estimation (SSE) from PsN to 
account for parameter uncertainty. The parameter uncer-
tainty was obtained from a sampling importance resampling 
(SIR) procedure.34 The covariate distribution in the simula-
tion dataset was derived from 186 pregnant and postpar-
tum women of the European Pharmacokinetics of newly 
developed ANtiretroviral agents in HIV-infected pregNAnt 
women (PANNA) study (www.panna study.com). These 
covariates were resampled, maintaining the covariate struc-
ture, 3000 times with 10% noise. Simulations were con-
ducted without residual error.
Six scenarios were evaluated: the concentration-time 
curve of pregnant and nonpregnant women treated with ralte-
gravir 1200 mg q.d. at steady-state under fasted, low-fat, and 
moderate-fat conditions. High-fat conditions were not simu-
lated because the model did not perform sufficiently under 
these conditions and it was not believed to be a commonly 
occurring meal type (~1000 kcal and 50% fat). We assumed 
that postpartum weight was similar to nonpregnant weight. 
The same 3000 individuals were simulated under the six dif-
ferent conditions. The AUC0–24h was derived from the model 
and the Ctrough was defined as the individual predicted con-
centration on 24 h after drug intake.
Target values simulation
As a proxy for efficacy, the Ctrough of pregnant women on the 
1200 mg q.d. raltegravir dosing regimen was compared with 
the same metric in nonpregnant women. The lower bound of 
the 90% confidence interval (CI) of the GMR Ctrough of preg-
nant / nonpregnant women was defined to be greater than 0.75, 
similarly to the target established in drug-drug interaction 
studies with the raltegravir 1200  mg regimen by the manu-
facturer and regulatory authorities.21,35 A secondary outcome 
parameter was the proportion of individuals with a Ctrough less 
than 0.020  mg/L among pregnant compared with nonpreg-
nant women using 1200 mg q.d. This target was derived from 
the ROC curve from the pharmacokinetic data of the inferior 
800 mg q.d. regimen (converted from 45 nM by calculating 
with a raltegravir molar mass of 0.0004444 mg/nmol).12
Additionally, the simulated GMRs were compared with 
the clinical data of two women included in the PANNA 
study. This European, open-label, multicenter, within-pa-
tient, pharmacokinetic Phase 4 study includes pregnant 
women living with HIV using raltegravir 1200 mg q.d. At 
third trimester (~33  weeks) and postpartum (preferably 
4–6 weeks), EDTA blood samples were collected at 0, 0.5, 
1, 2, 3, 4, 6, 8, 12, and 24 h after observed intake of ralte-
gravir with moderate-fat food (650 kcal; 30 g fat). Plasma 
concentrations were centrally analyzed using a validated 
liquid chromatography-based assay (LLOQ 0.01  mg/L).36 
Pharmacokinetic parameters were determined using non-
compartmental analysis (Phoenix 64 version 8.1; Certara). 
The detailed protocol of this study has been described in an 
earlier publication.10
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RESULTS
Data from 11 studies with 226 individuals and 5772 sampling 
points were pooled. In the following order, we excluded 1164 
samples due to interacting comedication, 99 BLOQ values 
(while 70 were imputed as LLOQ/2) and 493 nonevaluable 
samples, as defined in the Methods section. Ultimately, the 
PopPK model was built with 221 individuals and 4016 sam-
pling points, as shown in Table 1.
A two-compartment model with first-order elimination 
and absorption through three sequential absorption compart-
ments best described the data. The structure of the model is 
depicted in Figure 1. The transit rate constant (ktr) was esti-
mated and MAT was based on Equation 1:
with n equals the number of transit compartments. We included 
log-normally distributed IIV on CL, Vc, Q, Vp, and the residual 
error, as well as log-normally distributed IOV between doses 
on F and MAT. IIV correlations on CL with Q, and Q with Vp 
were included (dOFV –62.5). A time-varying and log-normally 
distributed proportional error structure with one proportional 
error for first 3 h after drug intake and one for more than 3 h 
after drug intake was included to empirically account for the 
larger observed variability during the absorption phase com-
pared with the disposition phase (dOFV −112.7).2
The following covariate-parameter relationships were in-
cluded: a dichotomous covariate for intake with food (irrespec-
tive of meal type) on MAT (dOFV −46.76, 160% increase with 
food), a dichotomous covariate for atazanavir co-administration 
on CL (dOFV −12.43, 17% decrease with atazanavir), a dichot-
omous covariate for the 600 mg formulation on F (dOFV −5.88, 
21% increase with 600 mg formulation vs. 400 mg formulation), 
a dichotomous covariate for intake with a low-fat meal on F 
(dOFV −46.98, 45% decrease with a low-fat meal), a dichoto-
mous covariate for the 600 mg formulation on the magnitude of 
IOV in F (dOFV −127.31, 72% decrease with 600 mg formula-
tion vs. 400 mg formulation), a dichotomous covariate for efa-
virenz co-administration on F (dOFV −5.28, 17% decrease with 
efavirenz), and a dichotomous covariate for being pregnant on F 
(dOFV −17.82, 49% decrease during pregnancy). The sensitivity 
analysis for the pregnancy covariate is included in the Supporting 
Information. The final population estimates are shown in Table 2.
A VPC based on 1000 samples and stratified for preg-
nancy and tablet formulation, is shown in Figure 2. This VPC 
indicated an adequate model fit to the observed concentra-
tion-time data. Standard goodness-of-fit plots indicated no 
bias in the structural model or unaccounted data heterogene-
ity (Supporting Information).
ktr = n + 1∕MAT(1)
F I G U R E  1  Final model structure. CL, clearance; Ktr, first-order transit rate; Ka, first-order absorption rate; Q, intercompartmental clearance; 
Vc, central volume of distribution; Vp, peripheral volume of distribution.
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A 21% higher bioavailability (relative standard error [RSE] 
26%) was estimated for the 600 mg tablets in comparison to 
the 400  mg tablets, and a 49% lower bioavailability (RSE 
14%) was estimated in pregnant compared with nonpregnant 
women. Predictions of raltegravir AUC0-24h and Ctrough in preg-
nant women treated with 1200 mg q.d. raltegravir are shown 
in Table 3. The predicted geometric mean (GM; 95% CI) ral-
tegravir Ctrough was 0.024 (0.002–0.133), 0.014 (0.001–0.086), 
0.027 (0.003–0.160) mg/L in pregnant women treated with 
1200 mg q.d. raltegravir in fasted, low-fat, and moderate-fat 
conditions, respectively. Simulations of nonpregnant and preg-
nant women treated with 1200 mg q.d. raltegravir showed that 
the GMR (90%CI) was 0.51 (0.41–0.63; Table 3). The lower 
bound of the 90% CI GMR was not greater than 0.75, hence 
the primary efficacy target was not fulfilled.
The predicted proportion with a Ctrough less than 0.020 mg/L 
was substantially higher in pregnant women compared with 
nonpregnant women using 1200 mg q.d.. Under fasted condi-
tions, 36.5% of the simulated pregnant women had a Ctrough less 
than 0.020 m/L, compared with 17.1% of the simulated non-
pregnant women. This was 58.6 versus 31.7%, and 33.7% ver-
sus 15.2% for low-fat and moderate-fat conditions, respectively.
These results were similar compared with the clinical data 
of two pregnant women from the PANNA study, as depicted 
in Figure 3. Woman number 1 was cotreated with darunavir/
ritonavir 800/100 mg q.d. At 33 weeks gestational age, raltegra-
vir AUC0–24h and Ctrough were 16.25 mg*h/L and 0.012 mg/L, 
respectively. At 4 weeks postpartum, raltegravir AUC0–24h and 
Ctrough were 22.72 mg*h/L and 0.027 mg/L, respectively. This 
corresponds to a Ctrough ratio pregnant / nonpregnant of 0.52. 
The second woman was cotreated with emtricitabine / teno-
fovir disoproxil fumarate 200 / 245  mg and an AUC0–24h of 
13.09 mg*h/L and Ctrough of less than 0.01 mg/L was estimated 
at 32  weeks gestational age. At 5  weeks postpartum, we as-
sessed an AUC0–24h of 27.24 mg*h/L and Ctrough of 0.015 mg/L. 
Although BLOQ during the third trimester, the Ctrough was mea-
surable and we calculated an approximate Ctrough ratio pregnant 
/ nonpregnant of 0.46. Although these women had a Ctrough less 
than 0.020 mg/L at the third trimester, both women had an HIV 
RNA viral load less than 50 copies/mL at the third trimester and 
at the postpartum visit. Woman number 1 delivered a healthy 
boy of 4010 gram at 40 weeks gestational age. The boy had a 
negative HIV viral load at delivery. The healthy boy of woman 
number 2 was born at 39 weeks of gestational age, was 2886 
gram, and also had a negative HIV viral load at delivery.
DISCUSSION
With this PopPK model, we performed a first evaluation of 
the drug exposure with the 1200  mg q.d. raltegravir regi-
men in pregnant women. We estimated that physiological 
changes during the third trimester of pregnancy decrease the 








MAT, h, fasted 0.336 8
Factor change in MAT feda 1.6 19
Vc/F, L
b 44.3 7
CL/F, L/hb 55.8 5
Factor change in CL with atazanavira −0.17 25




Factor change in F 600 mg formulationa 0.209 26
Factor change in F low-fat meala −0.459 9
Factor change in F pregnancya −0.487 14
Factor change in F efavirenz 
co-administrationa 
−0.167 37
IIV Vc/F, % 69.7
d 14e 
IIV CL/F, % 28.6d 6e 
Correlation coefficient with Q/F 0.18 41
IIV Q/F, % 71.5d 12e 
Correlation coefficient with Vp/F 0.59 10
IIV Vp/F, % 115.2
d 22e 
IIV residual error, % 25.6d 5e 
IOV F, %, 400 mg formulation 112.1d 17e 
Factor change in IOV in F 600 mg 
formulationf 
−0.718 4
IOV MAT (%) 140.5d 21 e 
Proportional residual error ≤ 3 h after 
drug intake, %
43.5d 3 e 
Proportional residual error > 3 h after 
drug intake, %
29.0d 2 e 
Abbreviations: CL/F apparent clearance; F, bioavailability; IIV, interindividual 
variability; IOV, interoccasion variability; Ka, first-order absorption rate; MAT, 
mean absorption time; Q/F, apparent intercompartmental clearance; RSE, 
relative standard error; SIR, sampling importance resampling; Vc/F, apparent 
central volume of distribution; Vp/F, apparent peripheral volume of distribution.
aThe covariate effects of fed conditions on MAT, atazanavir on CL, 600 mg 
formulation on F, low-fat meal on F, pregnancy on F, efavirenz on F and 600 mg 
formulation on IOV F were obtained with: MAT in fed conditions = MAT 
fasted * (1 + factor change in MAT fed); CL when atazanavir co-
administration = clearance * (individual weight / 70) 0.75 * (1 + factor change 
in CL with atazanavir); F in pregnancy, 600 mg formulation, low-fat meal and 
efavirenz co-administration = 1 * (1 + factor change in F 600 mg formulation) 
* (1 + factor change in F low-fat meal) * (1 + factor change in F pregnancy) * 
(1 + factor change in F efavirenz-co-administration). 
bFor the typical individual weighing 70 kg. 
cThe reference case for F is non-pregnant, the 400 mg formulation, other food 
conditions as low-fat, and no efavirenz co-administration. 
dTransformed from log normal variance to %CV with √(exp(variance)-1). 
eTransformed individual SIR results from log normal variance to %CV with 
√(exp(variance)-1) for calculation of the relative standard error. 
fThe covariate effect of 600 mg formulation on the IOV F was obtained with: 
(1 + factor change in IOV in F 600 mg formulation) * IOV F 400 mg formulation. 
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bioavailability of raltegravir with 49% compared with non-
pregnant women. The predetermined primary target was not 
met, and simulations predicted that a substantial part of the 
pregnant women treated with 1200  mg q.d. had an antici-
pated Ctrough less than 0.020 mg/L.
The primary target was set on the basis of the criteria of 
the 1200  mg q.d. regimen used in interaction studies from 
the manufacturer and the submission to the European regula-
tory authority.21,35 No pharmacokinetic target has been estab-
lished for the raltegravir 1200 mg q.d. regimen, as no clear 
relationship between plasma concentrations and virologic re-
sponse has been established up until now for this regimen.7 
Therefore, we believe that a conservative approach is suit-
able, aiming at a marginal deviation from the general popula-
tion for which efficacy has been demonstrated. The efficacy 
of the 1200 mg q.d. regimen was shown in a noninferiority 
trial in a population of treatment-naïve adults (n = 797) with 
HIV RNA greater than 1000 copies/ml with a median (in-
terquartile range) raltegravir Ctrough of 0.050 (0.028–0.094) 
mg/L.7
F I G U R E  2  Visual predictive check of the final model (simulations n = 1000). The observations are indicated by black dots. The median 
(continuous line) and 2.5th and 97.5th percentiles (dashed lines) of the observations are shown. The gray shaded areas indicate the 95% confidence 
interval around the median, 2.5th and 97.5th percentile of the simulated data. Vertical markers are sampling points.
Non−pregnant, 400mg tablet
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We predicted that a substantial proportion of the pregnant 
women using raltegravir 1200 mg q.d. will have a Ctrough less 
than 0.020 mg/L. This Ctrough target was derived from a study 
with raltegravir 800 mg q.d. in treatment-naïve patients with 
a high viral HIV load at baseline, so this target may not be 
applicable to our population.12 In addition, the Ctrough, Cmax, 
and AUC relate differently to each other for the 1200 mg q.d. 
dosing regimen compared with the 400 mg b.i.d. and 800 mg 
q.d. regimens, and it remains unclear whether this Ctrough tar-
get can be applied to other dosing regimens. Clinical data 
suggest that the Ctrough target is not applicable to the 1200 mg 
q.d. regimen because no direct relationship between a low 
Ctrough (median Ctrough of 0.019 mg/L in the lowest quartile) 
and virologic failure could be observed in 797 participants 
during the Phase 3 study with the 1200 mg q.d. regimen.13
The current PopPK modeling and simulating approach 
has several limitations. Raltegravir plasma concentrations 
show high variability between and within individuals due 
to the erratic absorption, making model development and 
derivation of significant covariates challenging. Various 
tested absorption models were not able to well describe the 
variable absorption with multiple peaks of raltegravir, an 
empirical time-varying residual error model was included.2 
Furthermore, we assumed that physiological changes 
during pregnancy had a similar effect on the 400 mg as on 
the 600 mg formulation. This is theoretically expected for 
the pregnancy effects, such as the possible increased vol-
ume of distribution and increased clearance. However, the 
possibly increased gastric pH, decreased gastric emptying, 
and increased intestinal transit time in pregnant women 
could impact both formulations differently.37,38 The 600 mg 
tablet is believed to disintegrate and dissolute faster as the 
400 mg tablet, and a diminished influence of concomitant 
high-fat food intake has been observed for the 600 mg tab-
let.8 Because research indicates that the gastrointestinal 
changes during pregnancy have an overall minimal effect 
on the bio-availability of drugs,39 and because the absorp-
tion of raltegravir is multifactorial and highly variable, we 
expect that the different gastrointestinal pregnancy effect 
on both formulations are likely to be negligible. The in-
fluence of physiological changes during pregnancy can 
also differ for the divergent food conditions and we based 
our conclusion on pregnancy data with moderate-fat food 
conditions only. We were also not able to test the effect of 
a moderate-fat meal on raltegravir pharmacokinetics sep-
arately, because this individual data was not available to 
use. We based the absence of a moderate-fat meal effect 
on F on earlier pharmacokinetic research.33 Total raltegra-
vir concentrations were predicted with our PopPK model, 
whereas the unbound raltegravir concentration functions as 
the active motion. The unbound drug fraction can change 
during pregnancy because the plasma protein concentra-
tion decrease.3,40 No data of unbound raltegravir concen-
tration was available to us, but the difference in raltegravir 
unbound fraction is expected be marginal as raltegravir is 
modestly bound to plasma proteins (~83%).35
Adequate performance of our simulations with the 
1200  mg q.d. regimen is indicated by comparisons to 
earlier data. A historical, small, multiple-dose, pharma-
cokinetic study determined an GM AUC0–24h and Ctrough 
of 26.46 mg*h/L and 0.036 mg/L in nonpregnant women 
in fasted state, which are similar to our predictions of 
25.45  mg*h/L and 0.047  mg/L, respectively.8 The pre-
dicted pharmacokinetic parameters of pregnant women 
F I G U R E  3  Comparison of the simulated GMR pregnant / nonpregnant Ctrough with the ratio derived from the clinical data of two pregnant 
women. The median (solid line) and 5th and 95th (dashed line) percentiles of the simulated GMR Ctrough are shown. The ratio third trimester / 
postpartum Ctrough of the two clinical cases are indicated by the dot-dashed line. Ctrough, concentration before next dose administration; GMR, 
geometric mean ratio.
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using 1200 mg q.d. were also similar to the clinical data of 
two pregnant women from the PANNA study. The Ctrough 
ratio pregnant / postpartum of these two women fell in the 
90% CI of our predicted Ctrough GMR. These subjects had 
an adequate virological response and no mother-to-child 
transition occurred.
Simulations with a PopPK model of raltegravir 1200 mg 
q.d. in pregnant women suggested inadequate raltegravir 
exposure during the third trimester of pregnancy. There is, 
however, a limited knowledge on the concentration-efficacy 
relationship of the 1200 mg q.d. regimen. Therefore, it is dif-
ficult to establish whether the inadequate exposure results in 
inadequate response. Although the limited, available clinical 
data (with lower raltegravir exposures) suggested an ade-
quate virologic response, data of two cases are not powered 
to support clinical efficacy of raltegravir 1200 mg q.d. during 
pregnancy. A conservative approach restraining the use of 
the q.d. regimen in pregnant women seems reasonable until 
additional research confirms that ~50% lower raltegravir ex-
posures for the raltegravir 1200 mg q.d. regimen remain ef-
fective. The raltegravir 400 mg b.i.d. regimen demonstrated 
adequate efficacy and safety during pregnancy and is a good 
alternative for these women. When treatment with raltegravir, 
1200 mg is believed to be necessary in a pregnant woman, in-
tensive viral load monitoring, and opportunistic collection of 
clinical and pharmacokinetic data is advised.
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